Citation: | CHEN Shuai, HU Weilie, OUYANG Keyu, NIE Qiwei, WANG Wei. Inhibitory Effect of Silencing PCAF Gene on Growth and Angiogenesis of Human Adrenocortical Carcinoma Xenograft in Nude Mice[J]. Cancer Research on Prevention and Treatment, 2015, 42(05): 454-458. DOI: 10.3971/j.issn.1000-8578.2015.05.007 |
[1] |
Chouairy CJ, Abdul-Karim F, Maclennan GT. Adrenocortical carcinoma[J]. J Urol, 2008, 179(1): 323.
|
[2] |
Kuruba R, Gallagher SF. Current management of adrenal tumors[J]. Curr Opin Oncol, 2008, 20(1): 34-46.
|
[3] |
Zhu C, Qin YR, Xie D, et al. Characterization of tumor suppressive function of P300/CBP-associated factor at frequently deleted region 3p24 in esophageal squamous cell carcinoma[J]. Oncogene, 20 09, 28(31): 2821-8.
|
[4] |
Nie QW. Apreliminary study of the impact of down-regulated PCAF on biological behavior of adredal cortex cell lines SW13 and its mechanisms[D]. Nan Fang Yi Ke Da Xue, 2014. [聂奇伟. 沉默基因PCAF对肾上腺皮质癌细胞株SW13生物学行为影响 及其机制的初步研究[D]. 南方医科大学, 2014.]
|
[5] |
Weidner N. Intratumor microvessel density as a prognostic factor in cancer[J]. Am J Pathol, 1995, 147(1): 9-19.
|
[6] |
Menon V, Krishnamurthy SV. Adrenocortical carcinomas: a 12-year clinicopathologic study of 15 cases[J]. Indian J Pathol Microbiol, 20 06, 49(1): 7-11.
|
[7] |
Ozda? H, Batley SJ, Försti A, et al. Mutation analysis of CBP and PCAF reveals rare inactivating mutations in cancer cell lines but not in primary tumours[J]. Br J Cancer, 2002, 87(10): 1162-5.
|
[8] |
Regina S, Rollin J, Bléchet C, et al. Tissue factor expression in non-small cell lung cancer: relationship with vascular endothelial growth factor expression, microvascular density, and K-ras mutation[J]. J Thorac Oncol, 2008, 3(7): 689-97.
|
[9] |
Cai RX, Sheng X, Yuan ZH, et al. Expression of CD105, COX-2 and VEGF and their relationship with angiogenesis in colorectal carcinoma[J]. Zhong Liu Fang Zhi Yan Jiu, 2007, 34(2): 125-7. [蔡 瑞霞, 盛霞, 袁志浩, 等. CD105、COX-2和VEGF在结直肠癌中 的表达及其与血管新生的关系[J]. 肿瘤防治研究, 2007, 34(2): 12 5-7.]
|
[10] |
Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF[J]. Science, 1999, 284(5422): 1994-8.
|
[11] |
Fukuda R, Hirota K, Fan F, et al. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells[J]. J Biol Chem, 2002, 277(41): 38205-11.
|
[12] |
Wang GL, Jiang BH, Semenza GL. Effect of altered redox states on expression and DNA-binding activity of hypoxia-inducible factor 1[J]. Biochem Biophys Res Commun, 1995, 212(2): 550-6.
|
[13] |
Lim JH, Lee YM, Chun YS, et al. Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1a lpha[J]. Mol Cell, 2010, 38(6): 864-78.
|
[14] |
Rajendran R, Garva R, Ashour H, et al. Acetylation mediated by the p300/CBP-associated factor determines cellular energy metabolic pathways in cancer[J]. Int J Oncol, 2013, 42(6): 1961-72.
|
[15] |
Ying MZ, Wang JJ, Li DW, et al. The p300/CBP associated factor is frequently downregulated in intestinal-type gastric carcinoma and constitutes a biomarker for clinical outcome[J]. Cancer Biol Ther, 2010, 9(4): 312-20.
|
[16] |
Hirano G, Izumi H, Kidani A, et al. Enhanced expression of PCAF endows apoptosis resistance in cisplatin-resistant cells[J]. Mol Cancer Res, 2010, 8(6): 864-72.
|
[17] |
Shiota M, Yokomizo A, Tada Y, et al. P300/CBP-associated factor regulates Y-box binding protein-1 expression and promotes cancer cell growth, cancer invasion and drug resistance[J]. Cancer Sci, 20 10, 101(8): 1797-806.
|
[1] | XIA Lei, WANG Xudong, YANG Gen, ZHU Hua, YANG Zhi. Progress in Mesothelin as Target for Cancer Specific Radionuclide Imaging[J]. Cancer Research on Prevention and Treatment, 2018, 45(9): 691-694. DOI: 10.3971/j.issn.1000-8578.2018.18.0087 |
[2] | XU Qing, YANG Min, LUO Shineng. Recent Advances in Radionuclide-labeled Analogues of Exendin-4 for Insulinoma Imaging[J]. Cancer Research on Prevention and Treatment, 2015, 42(04): 407-411. DOI: 10.3971/j.issn.1000-8578.2015.04.020 |
[3] | LAI Can-hui, YANG Jian-wei, ZHANG Jiang-ling, CHEN Shao-yi, CHEN Yun-bin, TANG Ming-deng. Study of Value of 18F-FDG SPECT/CT in Evaluation of Treatment Response in Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2010, 37(06): 679-682. DOI: 10.3971/j.issn.1000-8578.2010.06.019 |
[5] | LIU Yong, JIA Shi-quan, ZHANG Yi-fan, HAO Wei-dong. Clinical Study of All-trans-retinoic Acid in Redifferentiation Therapy for Thyroid Cancer[J]. Cancer Research on Prevention and Treatment, 2006, 33(09): 675-678. DOI: 10.3971/j.issn.1000-8578.1312 |
[6] | ZHAO Shui-xi, ZHENG Jing-chen, CAO Jing-xu, NIN Jian, WANG Ying-xuan, FU Shu-yun, YANG Shu-ming, ZHAO Wei-dong, BU Jie, MU Xiao-feng. Observations of CT Images and Biochemistry Changes on Radiation-induced Hepatic Injury[J]. Cancer Research on Prevention and Treatment, 2006, 33(05): 361-363. DOI: 10.3971/j.issn.1000-8578.2892 |
[7] | FAN Hai-tao, REN Ming, BAI Li-gang, WANG Hai-ying, LIU Lu-cheng. Inhibiting Effect of 125I-coupled Vascular Endothel ial Growth Factor ( VEGF) Antisense Oligonucleotides on Expression of VEGF in Bladder Cancer Cells[J]. Cancer Research on Prevention and Treatment, 2005, 32(10): 632-633. DOI: 10.3971/j.issn.1000-8578.545 |
[8] | YIN Tie jun, XIANYU Zhi qun, HU Chang yao. A study on pain relief of malignant bone metastasis with ~(89)Sr radionuclide therapy[J]. Cancer Research on Prevention and Treatment, 2003, 30(03): 233-235. DOI: 10.3971/j.issn.1000-8578.2713 |
[9] | Li Zongwei, . Value of Diagosis with Radionuclide (99mTC-MDP)Bone Imaging A Report of 51 cases[J]. Cancer Research on Prevention and Treatment, 1997, 24(3): 186-188. |
[10] | Chen Sheng-bo, et al, . 175 Patients with Various Carcinomas Whole-body Imaging[J]. Cancer Research on Prevention and Treatment, 1996, 23(4): 229-231. |